Article Text

FRI0148 Non-Adherence and Non-Persistence in the Therapy of Rheumatoid Arthritis with Methotrexate: An Analysis of German Claims Data Based on 9,592 RA Patients
  1. S. Mueller1,
  2. K. Krüger2,
  3. U. Maywald3,
  4. A. Fuchs3,
  5. J.-P. Flacke4,
  6. I. Haug-Rost4,
  7. H. Heinisch5,
  8. T. Wilke1
  1. 1Institut für Pharmakoökonomie und Arzneimittelogistik e.V. (IPAM), Wismar
  2. 2Praxiszentrum St. Bonifatius, Munich
  3. 3AOK Plus, Dresden
  4. 4Roche Pharma AG, Grenzach-Wyhlen
  5. 5Chugai Pharma Marketing Ltd., Frankfurt/M, Germany


Background According to current treatment guidelines Methotrexate (MTX) is the first-line choice of disease-modifying antirheumatic drug (DMARD) therapy of rheumatoid arthritis (RA). Previous studies indicated that non-persistence (NP)/non-adherence (NA) are widespread problems in the treatment of RA-patients. However, real world data addressing NP-/NA-problems are rare.

Objectives The purpose of this study was to describe the extent of NP/NA in RA-patients treated with MTX in Germany.

Methods Anonymous claims data from a German sickness fund (AOK PLUS) covering the years 2010-2013 were used. We included patients with at least one confirmed RA-diagnosis. However, all patients with an additional diagnosis of at least one of the following diseases were excluded: (e.g. axial spondyloarthritis, Bechterew's disease, psoriatic arthritis), NP was measured for patients who were newly treated with MTX orally/subcutaneously (no prescription of MTX in previous 12 months before index date); minimum observational period from first MTX-prescription onwards was 24 months. NP was defined as a medication gap of more than 12 weeks. Applied assumptions with regards to prescribed daily dosage (PDD) which was itself not available in the database were pre-tested in a validation study with 7 rheumatology practices which documented 935 prescriptions/their PDD for 160 RA-patients. Adherence was calculated using the medication possession ratio (MPR) between an observed first and last prescription (after confirmed RA-diagnosis); NA was defined as MPR<80%. The adherence was assessed since first until last prescription or, in case a patient became NP, until the first treatment gap >12 weeks was observed.

Results In total 62,204 RA-patients could be identified. Of these, 9,796 (15.7%) got at least one prescription of MTX after a RA-diagnosis. 204 patients with an intravenous application of MTX were also excluded. So, our analysis was based on 9,592 RA patients (mean age 64.4 years, 72.7% female, average Charlson Comorbidity Index of 4.1). Of these, 1,118 patients could be considered as newly treated (therapy start before end of 2011). Overall MTX-MPR from first prescription until end of the 24-months-observational period for these 1,118 patients was 60.7%. Of these patients, 379 patients (33.9%) discontinued MTX therapy (NP) within 24 months. For these, mean time to discontinuation was 29.1 weeks (median: 30). The observed NP rate was higher for oral MTX than for subcutaneous MTX (36.5% versus 29.8%). Adherence was calculated for a total of 8,345 patients. The average observed MPR was 90.4%; 19.4% of the patients could be classified as NA (23.1%/11.9% in patients with oral/subcutaneous application).

Conclusions More than 30% of the RA patients discontinue their MTX treatment early. Among patients still generally persisting with therapy, about 19% can be classified as NA. Approximately one third of newly treated patients and additional 19% of the persistent MTX-RA patients may be on NP/NA risk. So, this first analysis of a large German claims dataset showed that NA/NP is a considerable challenge in the real-world treatment of RA with MTX.

Disclosure of Interest S. Mueller Employee of: Institute for Pharmacoeconomics and Medication Logistics (IPAM), K. Krüger Consultant for: Roche, Speakers bureau: Roche, U. Maywald: None declared, A. Fuchs: None declared, J.-P. Flacke Employee of: Roche, I. Haug-Rost Employee of: Roche, H. Heinisch Employee of: Chugai, T. Wilke Consultant for: Roche, Novo Nordisk, GSK, BMS, LEO Pharma, Astra Zeneca, Bayer, Boehringer Ingelheim

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.